<ul>
<li>魔法蘑菇，现金流：Compass Pathways 的试验胜利，快速融资</li>
</ul>
<p>Compass Pathways PLC 赞助的 ADR (NASDAQ:CMPS - 免费报告) - HC Wainwright 的投资分析师在 3 月 2 日星期一发布的报告中对 Compass Pathways 的 2030 财年每股收益进行了估计。HC Wainwright 分析师 P. Trucchio 预测该公司在这一年将每股赚取 6.46 美元。HC Wainwright 目前对该股票给予 &#34;买入&#34; 评级，目标价为 70.00 美元。市场普遍预计 Compass Pathways 当前全年的每股收益为（-2.33 美元）。</p>
<p>获取 <strong>Compass Pathways</strong> 的提醒：</p>
<p>其他研究分析师也对该公司发布了报告。摩根士丹利在 2 月 18 日星期三的研究报告中将 Compass Pathways 的目标价从 11.00 美元上调至 18.00 美元，并给予该公司 &#34;超配&#34; 评级。Compass Point 在 2 月 12 日星期四的研究报告中设定了 Compass Pathways 的 15.00 美元目标价。Lifesci Capital 在 2 月 12 日星期四的报告中将 Compass Pathways 的评级上调至 &#34;强力买入&#34;。Weiss Ratings 在 1 月 21 日星期三的报告中重新发布了对 Compass Pathways 股票的 &#34;卖出（d-）&#34; 评级。最后，加拿大皇家银行在 2 月 18 日星期三的研究报告中将 Compass Pathways 股票的目标价从 21.00 美元上调至 22.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。一位投资分析师对该股票给予了强力买入评级，六位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价为 22.13 美元。</p>
<p><strong>阅读我们关于 Compass Pathways 的最新报告</strong></p>
<h2>Compass Pathways 股票表现</h2>
<p>Compass Pathways 股票在星期三开盘价为 6.95 美元。该公司的债务与股本比率为 0.55，流动比率为 1.23，速动比率为 1.23。该公司的 50 日简单移动平均为 6.98 美元，200 日简单移动平均为 6.12 美元。Compass Pathways 的 52 周低点为 2.25 美元，52 周高点为 8.90 美元。该公司的市值为 6.6734 亿美元，市盈率为 -2.56，贝塔值为 1.90。</p>
<h2>对 Compass Pathways 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 CMPS 的持仓进行了调整。Persistent Asset Partners Ltd 在第四季度新建了对 Compass Pathways 的持仓，价值约 38,000 美元。Advisory Services Network LLC 在第三季度新购入了价值约 41,000 美元的 Compass Pathways 股票。Caitong International Asset Management Co. Ltd 在第四季度新购入了价值约 47,000 美元的 Compass Pathways 股票。China Universal Asset Management Co. Ltd. 在第二季度将其在 Compass Pathways 的持股增加了 46.7%。China Universal Asset Management Co. Ltd. 目前拥有该公司 18,272 股股票，价值 51,000 美元，此前在上个季度又购入了 5,817 股。最后，BIT Capital GmbH 在第三季度新购入了价值约 54,000 美元的 Compass Pathways 股票。46.19% 的股票由机构投资者持有。</p>
<h2>Compass Pathways 公司简介</h2>
<p>（获取免费报告）</p>
<p>Compass Pathways NASDAQ: CMPS 是一家临床阶段的生物技术公司，专注于开发和商业化用于心理健康障碍的迷幻蘑菇疗法。该公司成立于 2016 年，总部位于伦敦，并在美国设有其他办事处，正在开创将合成迷幻蘑菇与心理治疗结合使用以应对难治性抑郁症的先河。该公司的旗舰项目是一个 IIb 期临床试验，评估其专有的迷幻蘑菇配方 COMP360，该配方已获得美国的突破性疗法认证。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Compass Pathways 更好</li>
<li>新发现富铜的 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>股票代码揭晓：预 IPO 获取 “下一个埃隆·马斯克” 公司的机会</li>
<li>白银的挤压正在加紧 - 机会正在形成</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Compass Pathways 吗？</h2>
<p>在你考虑 Compass Pathways 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Compass Pathways 并不在名单上。</p>
<p>虽然 Compass Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

CMPS

<p>HC Wainwright 分析师预测，Compass Pathways PLC（NASDAQ:CMPS）在 2030 财年每股收益将达到 6.46 美元，维持 “买入” 评级，目标价为 70 美元。其他分析师的评级和目标价各不相同，普遍评级为 “适度买入”，平均目标价为 22.13 美元。该股票开盘价为 6.95 美元，市值为 6.6734 亿美元。Compass Pathways 专注于用于心理健康障碍的迷幻蘑菇治疗，目前正在进行其专有配方 COMP360 的 IIb 期临床试验</p>

<ul>
<li>Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise</li>
</ul>
<div class="lb-trans"><ul>
<li>魔法蘑菇，现金流：Compass Pathways 的试验胜利，快速融资</li>
</ul>
</div><p>Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for Compass Pathways in a report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio forecasts that the company will earn $6.46 per share for the year. HC Wainwright currently has a &#34;Buy&#34; rating and a $70.00 target price on the stock. The consensus estimate for Compass Pathways' current full-year earnings is ($2.33) per share.</p>
<div class="lb-trans"><p>Compass Pathways PLC 赞助的 ADR (NASDAQ:CMPS - 免费报告) - HC Wainwright 的投资分析师在 3 月 2 日星期一发布的报告中对 Compass Pathways 的 2030 财年每股收益进行了估计。HC Wainwright 分析师 P. Trucchio 预测该公司在这一年将每股赚取 6.46 美元。HC Wainwright 目前对该股票给予 &#34;买入&#34; 评级，目标价为 70.00 美元。市场普遍预计 Compass Pathways 当前全年的每股收益为（-2.33 美元）。</p>
</div><p>Get <strong>Compass Pathways</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Pathways</strong> 的提醒：</p>
</div><p>Other research analysts have also issued reports about the company. Morgan Stanley increased their price objective on Compass Pathways from $11.00 to $18.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, February 18th. Compass Point set a $15.00 price target on Compass Pathways in a research note on Thursday, February 12th. Lifesci Capital upgraded Compass Pathways to a &#34;strong-buy&#34; rating in a report on Thursday, February 12th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Compass Pathways in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada upped their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $22.13.</p>
<div class="lb-trans"><p>其他研究分析师也对该公司发布了报告。摩根士丹利在 2 月 18 日星期三的研究报告中将 Compass Pathways 的目标价从 11.00 美元上调至 18.00 美元，并给予该公司 &#34;超配&#34; 评级。Compass Point 在 2 月 12 日星期四的研究报告中设定了 Compass Pathways 的 15.00 美元目标价。Lifesci Capital 在 2 月 12 日星期四的报告中将 Compass Pathways 的评级上调至 &#34;强力买入&#34;。Weiss Ratings 在 1 月 21 日星期三的报告中重新发布了对 Compass Pathways 股票的 &#34;卖出（d-）&#34; 评级。最后，加拿大皇家银行在 2 月 18 日星期三的研究报告中将 Compass Pathways 股票的目标价从 21.00 美元上调至 22.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。一位投资分析师对该股票给予了强力买入评级，六位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，平均目标价为 22.13 美元。</p>
</div><p><strong>Read Our Latest Report on Compass Pathways</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Compass Pathways 的最新报告</strong></p>
</div><h2>Compass Pathways Stock Performance</h2>
<div class="lb-trans"><h2>Compass Pathways 股票表现</h2>
</div><p>Shares of Compass Pathways stock opened at $6.95 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $6.98 and a 200 day simple moving average of $6.12. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The firm has a market cap of $667.34 million, a P/E ratio of -2.56 and a beta of 1.90.</p>
<div class="lb-trans"><p>Compass Pathways 股票在星期三开盘价为 6.95 美元。该公司的债务与股本比率为 0.55，流动比率为 1.23，速动比率为 1.23。该公司的 50 日简单移动平均为 6.98 美元，200 日简单移动平均为 6.12 美元。Compass Pathways 的 52 周低点为 2.25 美元，52 周高点为 8.90 美元。该公司的市值为 6.6734 亿美元，市盈率为 -2.56，贝塔值为 1.90。</p>
</div><h2>Hedge Funds Weigh In On Compass Pathways</h2>
<div class="lb-trans"><h2>对 Compass Pathways 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in CMPS. Persistent Asset Partners Ltd acquired a new position in Compass Pathways during the fourth quarter worth approximately $38,000. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways in the third quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways during the 4th quarter worth approximately $47,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Compass Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company's stock worth $51,000 after acquiring an additional 5,817 shares during the last quarter. Finally, BIT Capital GmbH acquired a new position in shares of Compass Pathways during the 3rd quarter worth approximately $54,000. 46.19% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 CMPS 的持仓进行了调整。Persistent Asset Partners Ltd 在第四季度新建了对 Compass Pathways 的持仓，价值约 38,000 美元。Advisory Services Network LLC 在第三季度新购入了价值约 41,000 美元的 Compass Pathways 股票。Caitong International Asset Management Co. Ltd 在第四季度新购入了价值约 47,000 美元的 Compass Pathways 股票。China Universal Asset Management Co. Ltd. 在第二季度将其在 Compass Pathways 的持股增加了 46.7%。China Universal Asset Management Co. Ltd. 目前拥有该公司 18,272 股股票，价值 51,000 美元，此前在上个季度又购入了 5,817 股。最后，BIT Capital GmbH 在第三季度新购入了价值约 54,000 美元的 Compass Pathways 股票。46.19% 的股票由机构投资者持有。</p>
</div><h2>Compass Pathways Company Profile</h2>
<div class="lb-trans"><h2>Compass Pathways 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.</p>
<div class="lb-trans"><p>Compass Pathways NASDAQ: CMPS 是一家临床阶段的生物技术公司，专注于开发和商业化用于心理健康障碍的迷幻蘑菇疗法。该公司成立于 2016 年，总部位于伦敦，并在美国设有其他办事处，正在开创将合成迷幻蘑菇与心理治疗结合使用以应对难治性抑郁症的先河。该公司的旗舰项目是一个 IIb 期临床试验，评估其专有的迷幻蘑菇配方 COMP360，该配方已获得美国的突破性疗法认证。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Compass Pathways</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Compass Pathways 更好</li>
<li>新发现富铜的 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>股票代码揭晓：预 IPO 获取 “下一个埃隆·马斯克” 公司的机会</li>
<li>白银的挤压正在加紧 - 机会正在形成</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Pathways Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compass Pathways 吗？</h2>
</div><p>Before you consider Compass Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compass Pathways 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Compass Pathways 并不在名单上。</p>
</div><p>While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 发布的 Compass Pathways 2030 财年收益预测